Stoke Therapeutics, Inc. (STOK) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
STOK's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
STOK Revenue Analysis (2017–2024)
As of March 1, 2026, Stoke Therapeutics, Inc. (STOK) generated trailing twelve-month (TTM) revenue of $205.6 million, reflecting explosive growth of +117.2% year-over-year. The most recent quarter (Q3 2025) recorded $10.6 million in revenue, down 23.1% sequentially.
Looking at the longer-term picture, STOK's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $36.6 million in 2024, representing a new all-time high.
Revenue diversification analysis shows STOK's business is primarily driven by License (80%), and Service (20%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), STOK has underperformed the peer group in terms of revenue growth. Compare STOK vs ALNY →
Peer Comparison
Compare STOK's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| STOKCurrent | $206M | +117.2% | - | -277.3% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $36.6M | +316.3% | $36.6M | 100.0% | $-101,372,000 | -277.3% |
| 2023 | $8.8M | -29.2% | $8.8M | 100.0% | $-114,773,000 | -1307.2% |
| 2022 | $12.4M | - | $12.4M | 100.0% | $-104,356,000 | -841.2% |
| 2021 | $0 | - | $0 | - | $-86,065,000 | - |
| 2020 | $0 | - | $-1,926,000 | - | $-53,044,000 | - |
| 2019 | $0 | - | $-450,000 | - | $-35,678,000 | - |
| 2018 | $0 | - | $-214,000 | - | $-12,781,000 | - |
| 2017 | $0 | - | $-113,000 | - | $-5,554,000 | - |
See STOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STOK Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare STOK vs AGIO
See how STOK stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is STOK's revenue growth accelerating or slowing?
STOK revenue is accelerating at +117.2% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $206M. Growth momentum has increased versus prior periods.
What is STOK's long-term revenue growth rate?
Stoke Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +117.2% is above this long-term average.
How is STOK's revenue distributed by segment?
STOK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.